Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Orphazyme. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Orphazyme's earnings available for a low price, and how does
this compare to other companies in the same industry?
Orphazyme is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Orphazyme is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Orphazyme's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Dr. Anders Mørkebjerg Hinsby, M.Sc., Ph.D. serves as the Chief Executive Officer at Orphazyme Aps. Dr. Hinsby was an Associate at BankInvest BioMedical Venture. Dr. Hinsby joined the BankInvest BioMedical Venture in 2006 and his focus is on analysis of scientific and intellectual property rights (IPR) as well as due diligence and manages five BankInvest investments. He is also responsible for assessing new business opportunities, with primary expertise in scientific and IPR analyses. Dr. Hinsby has extensive research experience within Biotech front-end technologies such as applied proteomics and bioinformatics as Assistant Professor at the Technical University of Denmark as well as from R&D functions in the Biotech industry. He has eight years of Biotech work experience with functions in R&D, IPR and Venture Capital. Prior to this, Dr. Hinsby worked as a Patent Attorney in Hoiberg a/s with focus on IPR strategies and due diligence for biotech companies. He serves on the Board of Santaris and Juvantia. He served as a Non Executive Director at F2G Ltd. He is the author or co-author of several papers in high-impact journals such as Molecular Cell and Nature Biotechnology. Dr. Hinsby has a Ph.D. in Medicine from the University of Copenhagen in 2004 and an M.Sc. in Human Biology.
Insufficient data for Anders to compare compensation growth.
Insufficient data for Anders to establish whether their remuneration is reasonable compared to companies of similar size in Denmark.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Orphazyme management team is about average.
Co-Founder & CEO
Co-Founder & Chief Scientific Officer
Chief Financial Officer
Chief Medical Officer
Chief Commercial Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Orphazyme board of directors is about average.
Do Institutions Own Orphazyme A/S (CPH:ORPHA) Shares?
Generally speaking, as a company grows, institutions will increase their ownership. … Conversely, insiders often decrease their ownership over time. … We also tend to see lower insider ownership in companies that were previously publicly owned.
Do Institutions Own Shares In Orphazyme A/S (CPH:ORPHA)?
If you want to know who really controls Orphazyme A/S (CPH:ORPHA), then you'll have to look at the makeup of its share registry. … Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … With a market capitalization of ø1.2b, Orphazyme is a small cap stock, so it might not be well known by many institutional investors.
What Kind Of Shareholder Appears On The Orphazyme A/S's (CPH:ORPHA) Shareholder Register?
Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … We also tend to see lower insider ownership in companies that were previously publicly owned. … Orphazyme is a smaller company with a market capitalization of ø1.3b, so it may still be flying under the radar of many institutional investors.
In this article, I will take a quick look at Orphazyme A/S’s (CPH:ORPHA) recent ownership structure – an unconventional investing subject, but an important one. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment.
What Should Investors Know About Orphazyme A/S's (CPH:ORPHA) Earnings Trend?
Orphazyme A/S's (CPSE:ORPHA) announced its latest earnings update in December 2017, which indicated that losses became smaller relative to the prrior year's level as a result of recent tailwinds Today I want to provide a brief commentary on how market analysts perceive Orphazyme's earnings growth outlook over the next couple of years and whether the future looks brighter. … CPSE:ORPHA Future Profit Mar 20th 18 Even though it’s helpful to be aware of the growth year by year relative to today’s value, it may be more beneficial to estimate the rate at which the business is moving on average every year. … The slope of this line is the rate of earnings growth, which in this case is 3.01%.
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of orphan protein-misfolding diseases. It focuses on developing therapies for diseases caused by misfolding of proteins and lysosomal dysfunction. The company’s lead candidate, Arimoclomol, is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. It also focuses on developing a series of heat-shock protein amplifying drugs. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.